Cargando…
PPARδ Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities
The prevalence of obesity in the USA and worldwide has reached epidemic proportions during the last two decades. Drugs currently available for the treatment of obesity provide no more than 5% placebo-adjusted weight loss and are associated with undesirable side effects. Peroxisome proliferator-activ...
Autores principales: | Perreault, Mylène, Erbe, David V., Tobin, James F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577153/ https://www.ncbi.nlm.nih.gov/pubmed/18989368 http://dx.doi.org/10.1155/2008/125387 |
Ejemplares similares
-
Atractylodin Ameliorates Colitis via PPARα Agonism
por: Heo, Gwangbeom, et al.
Publicado: (2023) -
High Sugar Intake and Development of Skeletal Muscle Insulin Resistance and Inflammation in Mice: A Protective Role for PPAR-δ Agonism
por: Benetti, Elisa, et al.
Publicado: (2013) -
Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism
por: Kroker, Alice J., et al.
Publicado: (2015) -
PPARδ Agonism Activates Fatty Acid Oxidation via PGC-1α but Does Not Increase Mitochondrial Gene Expression and Function
por: Kleiner, Sandra, et al.
Publicado: (2009) -
PPARβ/δ Agonism Upregulates Forkhead Box A2 to Reduce Inflammation in C2C12 Myoblasts and in Skeletal Muscle
por: Phua, Wendy Wen Ting, et al.
Publicado: (2020)